Search

Your search keyword '"Harlin, Olof"' showing total 19 results

Search Constraints

Start Over You searched for: Author "Harlin, Olof" Remove constraint Author: "Harlin, Olof"
19 results on '"Harlin, Olof"'

Search Results

1. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study

2. MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis

3. Poster: MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies

4. MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies

5. Poster: MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis

6. HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)-Subgroup Analysis

7. Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies.

8. HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed to Prior Alkylator Therapy-Subgroup Analysis

9. IFNα and IFNγ Impede Marek’s Disease Progression

11. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab

12. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab

13. TRUST - A Study to Evaluate an Integrated Approach for Optimized Patient Management in Multiple Sclerosis Patients Treated with Natalizumab - First Analysis of Baseline Data (P2.147)

14. Die Bedeutung von Interferon alpha und Interferon gamma auf den Verlauf der Marekschen Krankheit beim Haushuhn

19. Synthesis of IFN-beta by virus-infected chicken embryo cells demonstrated with specific antisera and a new bioassay.

Catalog

Books, media, physical & digital resources